DUBLIN AND CAMBRIDGE, Mass. – Medtronic has teamed up with IBM Watson Health to develop the Sugar.IQ smart diabetes assistant, an intelligent app designed to simplify and improve daily diabetes management. The app leverages artificial intelligence and analytic technologies from IBM Watson Health to continually analyze how an individual’s glucose level responds to their food intake, insulin dosages, daily routines, and other factors, including information provided by the app user, and reveal patterns that give actionable insight. The Sugar.IQ app is available to users of the Medtronic Guardian Connect continuous glucose monitoring system.
CHICAGO – Experts are applauding the American Medical Association’s recently issued policy on how to incorporate artificial and augmented intelligence into health care.
“The new guidelines get at one of the core challenges of integrating new technologies into health care—how we develop things that are actually going to be used,” said Dr. Cory Kidd, founder and CEO of Catalia Health, providers of the Mabu digital health platform.
The policy on AI states that the AMA will: leverage its ongoing engagement in digital health and other priority areas for improving patient outcomes and physician professional satisfaction to help set priorities for health care AI; identify opportunities to integrate the perspective of practicing physicians into the development and implementation of health care AI; encourage education for patients, physicians, medical students, other health care professionals in the promise and limitations of health care AI; and explore the legal implications of health care AI.
When new technologies like AI are introduced to health care, it’s important to ensure their proper use and safety, said Rick Berner, CEO of telehealth provider MDLive.
“We’re pleased to see the AMA is taking proactive stance to advance the use of AI to do what’s best for the patient and to provide quality care,” he said.
AI can be a big component in helping the industry rethink and disrupt health care by helping to automating routine clinician tasks, thereby making providers more efficient and able to see more patients, Berner said.
“AI will help us solve our physician shortage problem and make health care better for the patient and the provider, as well as lower costs and improve quality,” he said.
Guidelines like those developed by the AMA can also bring a greater understanding of AI’s potential, said Kidd.
“A lot of health care technology comes from developers trying to create solutions at a high level, but not from a day-to-day perspective,” he said. “Guidelines like these help connect the opportunities that technology can provide for automation and efficiencies with the clinicians who are actually going to use them.”
DANVILLE, Penn. – Geisinger Medical Center will use Jvion’s artificial intelligence-powered Cognitive Clinical Success Machine to improve chronic obstructive pulmonary disease-related readmissions, as well as avoidable COPD admissions. “The integration of Jvion’s solution is another step in the Institute’s plan to transform health care delivery by improving quality, outcomes and patient experience, while optimizing efficiencies,” said Dr. Karen Murphy, executive vice president, CIO and founding director of the Steele Institute for Healthcare Innovation at Geisinger, in a statement. “Leveraging demonstrated AI, we hope to accelerate our path to preventing patient illness and deterioration, optimizing patient care and improving patient health outcomes. Our goal is to apply the capabilities of the machine to drive significant improvements for some of the largest and most debilitating challenges that we face as healthcare providers.” Jvion’s Cognitive Clinical Success Machine uses Eigen-based technology to ask a series of questions about a patient’s health and risk. For each question, the machine delivers an individual patient’s risk, the clinical and non-clinical factors propelling the risk, and the most effective actions or interventions to mitigate the risk.
NEW YORK – Mount Sinai Health System and RenalytixAI are partnering to commercialize artificial intelligence solutions to improve kidney disease detection, management and treatment for patients with diabetes and other at-risk, large-scale patient populations. The partnership will leverage the health system’s data warehouse, and using de-identified clinical data, will create an advanced learning system to monitor and flag patients at risk for kidney disease and costly unplanned “crashes” into dialysis. “Our ability to apply the power of artificial intelligence against such a deep repository of clinical data, in combination with prognostic biomarkers, has the potential to change the game for all of our patients with diabetes and other populations at risk for kidney disease,” said Dr. Barbara Murphy, dean for clinical integration and population health management at the Icahn School of Medicine at Mount Sinai and chairwoman of the RenalytixAI scientific advisory board, in a statement. The first product launch is expected next year. “The fact that so many patients on dialysis have never seen a specialist has to change, both from a patient care and cost perspective,” said Julian Barnes, executive chairman of RenalytixAI, in a statement. “I believe that this partnership will result in RenalytixAI being leaders in the field of kidney care, alongside Mount Sinai.”
AMSTERDAM – The CareVoice has partnered with digital health platform provider Sensely on an artificial intelligence voice-based virtual health assistant for insurers and employers in Greater China. The AI-based symptom triage feature is integrated into the CareVoice platform, allowing insurance members to check their symptoms, access self-care content and find appropriate medical specialists. “We can rely on Sensely’s leading technology and solid evidence in terms of both member satisfaction and payer cost savings to fuel our value proposition to insurers and employers,” said Sebastien Gaudin, CEO and co-founder of The CareVoice, in a statement. Following a recent financing round, The CareVoice has upgraded its platform and mobile-based solutions with digitized claims, expanding its footprint in the private insurance market by partnering with more insurance services companies, as well as employers, he said.
LONDON – Great Ormond Street Hospital is partnering with Microsoft to develop artificial intelligence tools for children’s health. “We want to harness new technology, including AI, to deliver even better care and an enhanced patient experience,” said Dr. Peter Steer, CEO of Great Ormond Street Hospital, in a statement. “As data analytics become increasingly important in health care delivery, we want to ensure we have the right tools to provide the care that is more personalized and more effective.” The partnership will focus on machine learning, assisted decision-making and the use of medical chatbots. “This powerful partnership between GOSH and Microsoft is a potential game-changer for health care,” said Neil Sebire, chief research information officer at Great Ormond Street Hospital, in a statement. “It brings together academic and clinical expertise to be leveraged by the capabilities of Microsoft with the singular aim of improving health care for children.”
SAN FRANCISCO – First Derm has launched an artificial intelligence application programming interface to help assess any skin concern within one second. The company’s Skin Image Search using the API is in beta and will be improved upon on a monthly basis, by continuously training a deep convolutional neural network with skin disease images. First Derm, which began in 2014 as an anonymous, on-demand, online dermatology app, has collected hundreds of thousands anonymous, amateur skin disease images, which have been used for scientific research. “Thanks to an awesome team, we now have a great tool that can be used as a symptom checker for any skin concerns that we have named Skin Image Search,” said Dr. Alexander Börve, CEO and founder of First Derm, in a statement. First Derm’s AI API powers an online Skin Image Search tool, available online in any web browser. The tool has been trained on images of any skin condition, ranging from skin rashes, hair loss, nail issues, skin cancer lesions and genital concerns. The database helps match for similar images. The API can be integrated into any website, app or electronic health care record.
LONDON – Health technology startup Babylon Health is working with digital media and telecom conglomerate Tencent to leverage Babylon’s artificial intelligence system to deliver personal health assessments, treatment advice and individual health records across main land China. By interacting directly with users, Babylon’s AI system will be able to identify specific illnesses, provide health status assessments and triage necessary actions. “Tencent and Babylon share the same ethos about making health care accessible for all,” said Dr. Ali Parsa, CEO of Babylon Health, in a statement. “This is a partnership for Babylon to work with one of the tech giants in China, to bring quality digital health service to Chinese people.” Tencent’s WeChat platform has more than 1 billion users and the app has partnered with more than 38,000 medical facilities in China. Babylon is hoping to further expand its market reach and product capabilities by partnering with health care services around the world and has seen its membership grow to more than 1.4 million users. “We have identified Babylon as one of the leaders in this technology worldwide and aim to partner with them to put it into the hands of Chinese consumers,” said Meng Zhang, general manager of Tencent, in a statement.
SUNNYVALE, Calif. – Startup Memora Health has developed an artificial intelligence health coach, Felix, to support patients when they return home from the hospital. “A smartphone app that tracks your medication adherence and vital signs over time is hardly the coaching needed to make meaningful lifestyle changes,” said Nisarg Patel, CEO of Memora Health, in a recent blog post. “Patients need someone they can talk to, that can answer their questions, that can work with them day by day, one step at a time. Felix’s features an AI engine that allows a personalization and a conversational interface to simplify the patient user experience. Patients can use the SMS interface on any cell phone to talk to Felix to receive information and care support, ask questions about their treatment, mention challenges they’re facing, and report symptoms and side effects. The platform’s analytics engine identifies potentially dangerous symptoms from patient responses and can alert the patient, caregivers and clinicians in the event of an emergency. Felix is active 24/7 and immediately responds to patient questions and concerns to help them feel cared for at anytime, anywhere, and gets smarter as he talks to and learns from more patients. “Through our new platform, patients receive handcrafted chronic illness support and coaching, proactive medication and appointment reminders, treatment and drug information, and personalized follow-up questions to track patient-reported health outcomes, all personalized to their condition and treatments via text message,” said Patel.
LONDON – Health technology artificial intelligence company Medopad has raised $28 million in Series A funding toward a target of $120 million. The company’s health care technology data-capture platform connects patients and health care professionals in real time, enabling patients to continuously capture data through a broad set of modules and connected devices, then transmitting the collected data to health care professionals. “We now have several amazing strategic investors in the business, which is a great achievement for us as we gear up for significant growth and scale our business,” said Dan Vahdat, CEO of Medopad, in a statement. “Managing population health is one of the greatest challenges for governments across the world; we are proud to be at the forefront of solving this problem.” By improving the communication between patients and healthcare professionals, Medopad enables proactive early intervention, operational efficiencies and cost savings. The platform uses artificial intelligence to analyze collected data and develop predictive insights to detect life-threatening medical conditions. The company’s primary customers include hospitals, pharma companies, insurance companies and governments. Medopad has also announced that it has appointed industry leaders Stuart Fletcher, former CEO of BUPA Group, and Simon MacKinnon, chairman of Sinophi Healthcare, as non-executive directors.